Claims 1-7 (cancelled)

Claim 8 has been currently amended to read: A method of inhibiting angiogenesis in pathological conditions where increased angiogenesis and coincidental vascular perfusion are clinically detrimental, comprising the steps of:

producing an AT_4 receptor ~~antagonist~~ ligand with the structure NH_3^+-norleucine-tyrosine-isoleucine- histidine-COO^- , norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$, or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidine-proline-phenylalanine)-COO^-, and

administering the AT_4 receptor ~~antagonist~~ ligand.

Claim 9. (currently amended) The method of inhibiting angiogenesis accordingly to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand locally.

Claim 10. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intravascularly.

Claim 11. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intramuscularly.

Claim 12. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intraperitoneally.

Claim 13. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand subcutaneously.

Claim 14. (currently amended) The method of inhibiting angiogenesis according to claim 8, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand orally.

Claim 15 has been currently amended to read: A method of inhibiting the growth and metastasis of solid tumors, comprising the steps of:

producing an AT_4 receptor ~~antagonist~~ ligand with the structure NH_3^+-norleucine-tyrosine-isoleucine- histidine-COO^- , norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$, or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidne-proline-phenylalanine)-COO^-, and

administering the AT_4 receptor ~~antagonist~~ ligand.

Claim 16. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising delivery of the AT_4 receptor ~~antagonist~~ ligand locally.

Claim 17. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intravascularly.

Claim 18. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intramuscularly.

Claim 19. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intraperitoneally.

Claim 20. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT_4 receptor ~~antagonist~~ ligand subcutaneously.

Claim 21. (currently amended) The method of inhibiting the growth and metastasis of solid tumors according to claim 15, further comprising the step of applying the AT_4 receptor ~~antagonist~~ ligand orally.

Claim 22 has been currently amended to read: A method of inhibiting the growth and metastasis of breast cancer, comprising the steps of:

producing an AT_4 receptor ~~antagonist~~ ligand with the structure NH_3^+-norleucine-tyrosine-isoleucine- histidine-COO^-, norleucine-tyrosine-isoleucine-(6-amino-hexanoic acid)-$CONH_2$, or norleucine-tyrosine-leucine-Ψ-$(CH_2$-$HN_2)^{3-4}$-histidne-proline-phenylalanine)-COO^-, and

administering the AT_4 receptor ~~antagonist~~ ligand.

Claim 23. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand locally to the tumor.

Claim 24. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intravascularly.

Claim 25. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intramuscularly.

Claim 26. (currently amended) The method of inhibiting the growth and metastasis of breast cancer according to claim 22, further comprising the delivery of the AT_4 receptor ~~antagonist~~ ligand intraperitoneally.